| Name | Title | Contact Details |
|---|
Our groundbreaking plasma-based materials are designed to improve patient outcomes and reduce healthcare costs across a variety of surgical procedures.
Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.
HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world`s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere research institutions in the US, EU, and beyond. We secure lasting partnerships with inventors and their institutions, and provide the developmental, financial, and business acumen to bridge the gaps between discovery and clinical impact. With robust funding options, operations in greater Boston, Washington DC and New York City, growing affiliates in Seattle and Indianapolis, a wealth of opportunities in our pipeline, and partnerships with industry leaders worldwide, Celdara Medical navigates the path from science to medicine, accelerating innovation to improve human health. Celdara Medical - Transforming innovation into medicine.™
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.